共 50 条
- [31] Tesamorelin (Egrifta) for HIV-Associated Lipodystrophy [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1363): : 34 - 35
- [32] Effects of rosiglitazone on abnormal lipid kinetics in HIV-associated dyslipidemic lipodystrophy: a stable isotope study [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (06): : 754 - 760
- [33] Spotlight on Tesamorelin in HIV-Associated Lipodystrophy [J]. BIODRUGS, 2011, 25 (06) : 405 - 408
- [34] Pharmacologic therapy for HIV-associated lipodystrophy [J]. ANNALS OF PHARMACOTHERAPY, 2004, 38 (03) : 448 - 457
- [35] Leptin in congenital and HIV-associated lipodystrophy [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (01): : 47 - 59
- [36] HIV-associated lipodystrophy in South Africa: The impact on the patient and the impact on the plastic surgeon [J]. JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2013, 66 (06): : 839 - 844
- [40] Recombinant Human Growth HormoneRationale for Use in the Treatment of HIV-Associated Lipodystrophy [J]. BioDrugs, 2008, 22 : 101 - 112